Irving Fox Selected Research

Crohn Disease (Crohn's Disease)

1/2018	Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
11/2017	A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.
8/2017	Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
1/2017	The safety of vedolizumab for ulcerative colitis and Crohn's disease.
11/2016	Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.
9/2014	Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
11/2013	Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype.
8/2013	Vedolizumab as induction and maintenance therapy for Crohn's disease.
7/2013	Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease.
8/2012	Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Irving Fox Research Topics

Disease

10	Crohn Disease (Crohn's Disease) 01/2018 - 08/2012
9	Ulcerative Colitis 01/2018 - 08/2012
4	Infections 01/2017 - 08/2013
4	Neoplasms (Cancer) 01/2017 - 01/2015
2	Progressive Multifocal Leukoencephalopathy 01/2018 - 11/2013
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2018 - 07/2013
2	Necrosis 08/2017 - 01/2017
1	Body Weight (Weight, Body) 11/2017
1	Breast Neoplasms (Breast Cancer) 01/2017
1	Glioma (Gliomas) 12/2016
1	Anus Neoplasms (Anal Cancer) 01/2015
1	Intestinal Perforation 01/2015
1	Kidney Calculi (Kidney Stone) 01/2015
1	Headache (Headaches) 08/2013
1	Nasopharyngitis 08/2013
1	Abdominal Pain (Pain, Abdominal) 08/2013

Drug/Important Bio-Agent (IBA)

12	vedolizumabIBA 01/2018 - 08/2012
4	IntegrinsIBA 01/2017 - 08/2013
2	AlbuminsIBA 11/2017 - 08/2017
2	poly(malic acid)IBA 01/2017 - 12/2016
2	Monoclonal AntibodiesIBA 11/2016 - 07/2013
1	C-Reactive ProteinIBA 08/2017
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 08/2017
1	Antisense OligonucleotidesIBA 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2017
1	Analgesics (Analgesic Drugs)IBA 01/2017
1	Narcotics (Narcotic Analgesics)IBA 01/2017
1	ErbB Receptors (EGF Receptor)IBA 12/2016
1	epidermal growth factor receptor VIIIIBA 12/2016
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 12/2016
1	Tumor Necrosis Factor InhibitorsIBA 09/2014
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2014
1	Natalizumab (Tysabri)FDA Link 11/2013

Therapy/Procedure

6	Therapeutics 01/2018 - 08/2013
1	Intravenous Infusions 11/2017